Revolution Medicines, INC

Revolution Medicines announced first quarter 2026 financial results, highlighting positive Phase 3 trial data for daraxonrasib in pancreatic cancer and a significant capital raise.

Revolution Medicines, Inc. has issued $500 million in 0.50% convertible senior notes due 2033 to fund general corporate purposes.

Revolution Medicines, Inc. has successfully priced a $1.5 billion common stock offering and a $500 million convertible note offering to fund general corporate purposes.

Revolution Medicines announced statistically significant and clinically meaningful improvements in progression-free and overall survival for daraxonrasib in a Phase 3 pancreatic cancer trial.

Revolution Medicines announced its full year 2025 financial results and provided an update on its broad late-stage oncology pipeline, including five ongoing Phase 3 trials and plans for three more.

Revolution Medicines announced its third quarter 2025 financial results and provided updates on its late-stage oncology pipeline, including significant progress in RAS-addicted cancer trials.

Revolution Medicines, a clinical-stage precision oncology company, reported significantly increased net losses and R&D expenses in Q3 2025 as it aggressively advances its RAS(ON) inhibitor pipeline, securing new funding and regulatory designations.

Revolution Medicines, a clinical-stage oncology company, reported increased R&D expenses and net losses in Q2 2025, while securing a significant $250 million royalty financing and advancing its key RAS(ON) inhibitor programs with new Breakthrough Therapy Designations.

Revolution Medicines reports a net loss of $213.4 million for Q1 2025, alongside updates on its RAS(ON) inhibitor clinical programs.

Revolution Medicines reports its third quarter 2024 financial results, detailing ongoing clinical trials and financial position.

Revolution Medicines reports a net loss of $249.2 million for the first six months of 2024, while advancing its RAS(ON) inhibitor pipeline.

Revolution Medicines reports a net loss of $116 million for Q1 2024, while advancing its clinical-stage RAS(ON) inhibitor programs.

Revolution Medicines reports significant clinical advancements for its RAS(ON) inhibitor pipeline, including multiple FDA Breakthrough Therapy Designations, alongside increased R&D expenses and a net loss of $1.13 billion for 2025.

Revolution Medicines' 10-K filing summarizes the company's financial performance and clinical development progress in 2024, focusing on its RAS(ON) inhibitor programs.

Revolution Medicines provides a detailed description of its common stock, public warrants, private placement warrants, and earn-out shares in a recent SEC filing.

Revolution Medicines, Inc. Director Sushil Patel reported transactions involving the acquisition of stock options and the sale of common stock under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, reported a series of stock transactions on June 24, 2026, including the acquisition of stock options and the sale of common stock.

Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax obligations.

Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax withholding obligations.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,157 shares of common stock on June 16, 2026, to cover tax withholding obligations related to vested restricted stock units.

Revolution Medicines, Inc. reports a Form 4 filing detailing a transaction by insider Stephen Michael Kelsey.

Revolution Medicines has issued its 2026 proxy statement detailing director elections, auditor ratification, and executive compensation advisory votes.

Revolution Medicines has scheduled its 2025 Annual Meeting for June 26, 2025, where stockholders will vote on the election of directors, ratification of the company's accounting firm, and executive compensation.

Revolution Medicines will hold its 2025 Annual Meeting of Stockholders online on June 26, 2025, to vote on director elections, auditor ratification, and executive compensation.

Revolution Medicines has scheduled its 2024 Annual Meeting for June 20, 2024, and is urging stockholders to vote on key proposals, including the election of directors and ratification of the company's accounting firm.

Revolution Medicines will hold its 2024 Annual Meeting of Stockholders online on June 20, 2024, to vote on director elections, auditor ratification, and executive compensation.

Janus Henderson Group plc has reported a beneficial ownership of 4.9% of Revolution Medicines, Inc. common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in REVOLUTION Medicines Inc following an internal realignment.

Wellington Management Group LLP and its affiliates reported a 3.6% beneficial ownership stake in Revolution Medicines, Inc. common stock as of December 31, 2025.

Farallon Capital Management entities updated their beneficial ownership in Revolution Medicines, Inc., disclosing a 7.5% stake and internal management changes.

Janus Henderson Group plc has reported a 6.1% beneficial ownership stake in Revolution Medicines, Inc., holding over 11 million shares.

FMR LLC and Abigail P. Johnson have reported a 5.0% beneficial ownership stake in Revolution Medicines Inc. common stock as of September 30, 2025.